Chronic immune thrombocytopenic purpura—who needs medication?
- 124 Downloads
Chronic ITP (immune thrombocytopenic purpura; now defined as duration of more than 12 months) is not always associated with significant bleeding problems so that most children and adults can be managed expectantly with no medication unless surgery, accidents or other pathology mandate it. A cut-off platelet count of 30 × 109/l divides a group with no increased mortality from those whose risk is greater and in whom medication is usually appropriate. There is increasing recognition of long-term morbidity and mortality associated with immune suppression induced by medication and more recently new concerns have arisen about the long-term vascular complications of splenectomy. A more conservative approach to medication is warranted in many patients with chronic ITP.
KeywordsChronic ITP Immune thrombocytopenia Immune modulation Splenectomy
- 3.Rodeghiero F, Stasi R, Gernsheimer T, Michel M, Provan D, Arnold DM et al (2009) Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 113(11):2386–2393CrossRefPubMedGoogle Scholar
- 9.Cheng G, Gernsheimer T, Olney HJ, Bussel JB, Sha P, Brainsky A, Grotzinger KM, Aivado M (2009) Time to splenectomy failure in patients with recurrent or refractory chronic immune thrombocytopenic purpura. Blood abstract from the 2009 ASH conference accessed online (28 January 2010) at ash.confex.com/ash/2009/webprogram/Paper24795.htmlGoogle Scholar
- 20.Beck CE, Nathan PC, Parkin PC, Blanchette VS, Macarthur C (2005) Corticosteroids versus intravenous immune globulin for the treatment of acute immune thrombocytopenic purpura in children: a systematic review and meta-analysis of randomized controlled trials. J Pediatr 147:521–527CrossRefPubMedGoogle Scholar
- 23.Bone and Tooth Society of Great Britain, National Osteoporosis Society and Royal College of Physicians (2002) Glucocorticoid-induced osteoporosis. Guidelines for prevention and treatment. London: RCP, ISBN 1 86016 173 1Google Scholar
- 24.Carson KR, Evens AM, Richey EA, Habermann TM, Focosi D, Seymour JF et al (2009) Progressive multifocal leukoencephalopathy following rituximab therapy in HIV negative patients: a report of 57 cases from the Research on Adverse Drug Event and Reports (RADAR) project. Blood 113:4834–4840CrossRefPubMedGoogle Scholar